chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Herpes zoster
Clinical narrative: got moderate Shingles left back /T5 distribution; Pain; patches of blisters; itching; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.  The patient's past medical history included shingles (PMH - Shingles in 40s / original shingles in my 40s - left back -T5 distribution). Previously administered products included Zostavax with an associated reaction of herpes zoster (received about 15 years ago from reporting and would get verymild attacks of Shingles every few years in different parts of the body) and Shingrix with an associated reaction of herpes zoster (1st dose was received on 15-FEB-2023, refer case US2023AMR071494). Concurrent medical conditions included borderline diabetes and hypertension (mild). Additional patient notes included the patient was in excellent health. No immune compromised illnesses. Concomitant products included metformin and amlodipine.  On 27-APR-2023, the patient received the 2nd dose of Shingrix. In MAY-2023, 1 week after receiving Shingrix, the patient experienced shingles (Verbatim: got moderate Shingles left back /T5 distribution), pain (Verbatim: Pain), blister (Verbatim: patches of blisters) and pruritus (Verbatim: itching). Rechallenge with Shingrix was positive. The outcome of the shingles, pain, blister and pruritus were resolving.  It was unknown if the reporter considered the shingles, pain, blister and pruritus to be related to Shingrix.  It was unknown if the company considered the shingles, pain, blister and pruritus to be related to Shingrix.  Linked case(s) involving the same patient: US2023AMR071494  Additional Information: GSK Receipt Date: 17-MAY-2023 After the second vaccine, about 1 week later she got moderate Shingles left back T5 distribution (the same distribution as her original shingles in her 40s) with pain, patches of blisters and itching, still had the largest 2.5 cm patch but was definitely better compared to last week. She did not consult with her primary care physician because she knew the diagnosis and did not particularly thought antivirals were necessary. She did realize that generally, Shingrix vaccine was not associated with actually getting the Shingles, but she had afraid she definitely got it with both vaccines. With both vaccines, she did not experience much of other generalized symptoms (pain at the injection site with the second vaccine). Today (on the day of reporting), she had mentioned to pharmacist about her Shingles episodes after receiving recent Shingrix vaccines as she felt they needed to know. She was just letting GSK know about her experience with Shingrix vaccines just for GSK interest and nothing more. At the end of the day, she was very grateful that Shingrix vaccine was available for all and that hopefully, she would never get Shingles again. The reporter had consented to follow-up.
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Blister, Herpes zoster, Injection site pain, Pain, Pruritus
Clinical narrative: got moderate Shingles left back /T5 distribution; Pain; patches of blisters; itching; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.  The patient's past medical history included shingles (PMH - Shingles in 40s / original shingles in my 40s - left back -T5 distribution). Previously administered products included Zostavax with an associated reaction of herpes zoster (received about 15 years ago from reporting and would get verymild attacks of Shingles every few years in different parts of the body) and Shingrix with an associated reaction of herpes zoster (1st dose was received on 15-FEB-2023, refer case US2023AMR071494). Concurrent medical conditions included borderline diabetes and hypertension (mild). Additional patient notes included the patient was in excellent health. No immune compromised illnesses. Concomitant products included metformin and amlodipine.  On 27-APR-2023, the patient received the 2nd dose of Shingrix. In MAY-2023, 1 week after receiving Shingrix, the patient experienced shingles (Verbatim: got moderate Shingles left back /T5 distribution), pain (Verbatim: Pain), blister (Verbatim: patches of blisters) and pruritus (Verbatim: itching). Rechallenge with Shingrix was positive. The outcome of the shingles, pain, blister and pruritus were resolving.  It was unknown if the reporter considered the shingles, pain, blister and pruritus to be related to Shingrix.  It was unknown if the company considered the shingles, pain, blister and pruritus to be related to Shingrix.  Linked case(s) involving the same patient: US2023AMR071494  Additional Information: GSK Receipt Date: 17-MAY-2023 After the second vaccine, about 1 week later she got moderate Shingles left back T5 distribution (the same distribution as her original shingles in her 40s) with pain, patches of blisters and itching, still had the largest 2.5 cm patch but was definitely better compared to last week. She did not consult with her primary care physician because she knew the diagnosis and did not particularly thought antivirals were necessary. She did realize that generally, Shingrix vaccine was not associated with actually getting the Shingles, but she had afraid she definitely got it with both vaccines. With both vaccines, she did not experience much of other generalized symptoms (pain at the injection site with the second vaccine). Today (on the day of reporting), she had mentioned to pharmacist about her Shingles episodes after receiving recent Shingrix vaccines as she felt they needed to know. She was just letting GSK know about her experience with Shingrix vaccines just for GSK interest and nothing more. At the end of the day, she was very grateful that Shingrix vaccine was available for all and that hopefully, she would never get Shingles again. The reporter had consented to follow-up.
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Vaccine positive rechallenge
Clinical narrative: got moderate Shingles left back /T5 distribution; Pain; patches of blisters; itching; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.  The patient's past medical history included shingles (PMH - Shingles in 40s / original shingles in my 40s - left back -T5 distribution). Previously administered products included Zostavax with an associated reaction of herpes zoster (received about 15 years ago from reporting and would get verymild attacks of Shingles every few years in different parts of the body) and Shingrix with an associated reaction of herpes zoster (1st dose was received on 15-FEB-2023, refer case US2023AMR071494). Concurrent medical conditions included borderline diabetes and hypertension (mild). Additional patient notes included the patient was in excellent health. No immune compromised illnesses. Concomitant products included metformin and amlodipine.  On 27-APR-2023, the patient received the 2nd dose of Shingrix. In MAY-2023, 1 week after receiving Shingrix, the patient experienced shingles (Verbatim: got moderate Shingles left back /T5 distribution), pain (Verbatim: Pain), blister (Verbatim: patches of blisters) and pruritus (Verbatim: itching). Rechallenge with Shingrix was positive. The outcome of the shingles, pain, blister and pruritus were resolving.  It was unknown if the reporter considered the shingles, pain, blister and pruritus to be related to Shingrix.  It was unknown if the company considered the shingles, pain, blister and pruritus to be related to Shingrix.  Linked case(s) involving the same patient: US2023AMR071494  Additional Information: GSK Receipt Date: 17-MAY-2023 After the second vaccine, about 1 week later she got moderate Shingles left back T5 distribution (the same distribution as her original shingles in her 40s) with pain, patches of blisters and itching, still had the largest 2.5 cm patch but was definitely better compared to last week. She did not consult with her primary care physician because she knew the diagnosis and did not particularly thought antivirals were necessary. She did realize that generally, Shingrix vaccine was not associated with actually getting the Shingles, but she had afraid she definitely got it with both vaccines. With both vaccines, she did not experience much of other generalized symptoms (pain at the injection site with the second vaccine). Today (on the day of reporting), she had mentioned to pharmacist about her Shingles episodes after receiving recent Shingrix vaccines as she felt they needed to know. She was just letting GSK know about her experience with Shingrix vaccines just for GSK interest and nothing more. At the end of the day, she was very grateful that Shingrix vaccine was available for all and that hopefully, she would never get Shingles again. The reporter had consented to follow-up.
Age: 12.0
Sex: F
Vaccine: HPV9, HPV9, HPV9, HPV9, HPV9
Symptoms: No adverse event, Product storage error
Clinical narrative: No adverse event; temperature excursion total time: 25 mins, 3 excursions on dates 9/9/22 for 8 mins, 9/16/22 for 5 mins, 1/3/23 for 12 mins; This spontaneous report was received from an office manager and refers to a 12-year-old female patient. No information on patient medical history, current conditions and concomitant medications was provided.  On 20-DEC-2022, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dosage form, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites and routes of administration were not provided) administered for prophylaxis (product storage error and no adverse event).  Temperature excursion total time was 25 minutes. There were 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day. Patient was vaccinated in private doctor's office/hospital.  This is one of several reports received from the same reporter.  This is amended report. The aware date had to be changed from 10-MAY-2023 to 09-MAY-2023. This report is copy of case #2305USA004522, which is deteled from our files and was copied into this case. ; Sender's Comments:  US-009507513-2304USA002221:Source original: 2304USA002221
Age: 40.0
Sex: F
Vaccine: PNC15, PNC15
Symptoms: Angiogram pulmonary, Anticoagulant therapy, Pulmonary embolism
Clinical narrative: Developed pulmonary embolism the day after receiving PCV15
Age: 40.0
Sex: F
Vaccine: PNC15, PNC15
Symptoms: Computerised tomogram thorax abnormal, Pulmonary embolism
Clinical narrative: Developed pulmonary embolism the day after receiving PCV15
Sex: U
Vaccine: HPV9
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AE; temperature excursion; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's medical history, historical drugs, past drug reactions or allergies, concurrent conditions, and concomitant drugs were not reported.   On 12-MAY-2023, the patient was vaccinated with one dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) injection (lot#: W014513, expiration date: 26-JAN-2025; strength, dose, route of administration, and anatomical location were not reported) for prophylaxis. The vaccine administered experienced temperature at 52.86 F for 96 hours (product storage error). No additional adverse events (AE) (no adverse event).  This case was received from the same reporter with the case 2305USA005519. ; Sender's Comments:  US-009507513-2305USA005519:
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Expiration date was 26FEB2023 and date the vial was initially stored in the refrigerator on 14MAR2023; No adverse event; She had expired vaccine that was administered on March 15,2023 there was between 75 and 125 people that was vaccinated; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (She had expired vaccine that was administered on March 15,2023 there was between 75 and 125 people that was vaccinated), PRODUCT STORAGE ERROR (Expiration date was 26FEB2023 and date the vial was initially stored in the refrigerator on 14MAR2023) and NO ADVERSE EVENT (No adverse event) in a 34-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 060B22A) for COVID-19 prophylaxis.     It was unknown if patient had ever been diagnosed with/ tested positive for COVID-19.     On 15-Mar-2023, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 15-Mar-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (She had expired vaccine that was administered on March 15,2023 there was between 75 and 125 people that was vaccinated). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Expiration date was 26FEB2023 and date the vial was initially stored in the refrigerator on 14MAR2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (She had expired vaccine that was administered on March 15,2023 there was between 75 and 125 people that was vaccinated), PRODUCT STORAGE ERROR (Expiration date was 26FEB2023 and date the vial was initially stored in the refrigerator on 14MAR2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (She had expired vaccine that was administered on March 15,2023 there was between 75 and 125 people that was vaccinated) and PRODUCT STORAGE ERROR (Expiration date was 26FEB2023 and date the vial was initially stored in the refrigerator on 14MAR2023).    Concomitant medication was not reported.  Vial size was reported as 10 dose vial. The vial was initially stored in the refrigerator on 14-MAR-2023. The vial did not undergo any temperature excursions.  It was reported that HCP stated that expired Moderna COVID-19 monovalent vaccine was administered to approximately 75-125 patients on 15-MAR-2023. There was potentially a second lot number that was expired and was administered to patients on 3-MAR-2023, but HCP did not had any details on that event at the time of report.   Treatment medication was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-716065 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-716065:case
Age: 1.25
Sex: F
Vaccine: DTAP
Symptoms: Incorrect dose administered, Medication error, No adverse event, Product preparation error
Clinical narrative: inadvertently diluted daptacel with a sterile saline solution to 1ml with no reported adverse event; only 0.5ml of the diluted vaccine was administered with no reported adverse event; Initial information received on 16-May-2023 regarding an unsolicited valid non-serious case received from other health professional.  This case involves a 15 months old female patient who administered only 0.5ml of the Diphtheria-15/Tetanus/5 AC Pertussis vaccine [Daptacel] which was inadvertently diluted with a sterile saline solution to 1 ml with no reported adverse event with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included Measles vaccine, Mumps vaccine, Rubella vaccine (MMR) for Prophylactic vaccination.  On 09-May-2023, the patient received a dose 4, 0.5 ml dose, frequency: once; of suspect Diphtheria-15/Tetanus/5 AC Pertussis vaccine Suspension for injection of standard strength, with lot C5980AB and expiry: 06-Apr-2024 via intramuscular route in the right thigh for immunization; which was inadvertently diluted with a sterile saline solution to 1ml with no reported adverse event (product preparation error)(latency: same day) and only 0.5ml of the diluted vaccine was administered with no reported adverse event (incorrect dose administered) (latency: same day) following the administration of Diphtheria-15/Tetanus/5 AC Pertussis vaccine.  No lab data was reported.  Action taken was not applicable.  At time of reporting, the outcome was Unknown for the event inadvertently diluted daptacel with a sterile saline solution to 1ml with no reported adverse event and only 0.5ml of the diluted vaccine was administered with no reported adverse event.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 61.0
Sex: M
Vaccine: VARZOS
Symptoms: Irritability, Malaise, Pain in extremity, Pyrexia, Swelling
Clinical narrative: Malaise/feeling sick; Low grade fever; Sore arm; Swelling; This non-serious case was reported by a physician via sales rep and described the occurrence of feeling unwell in a 61-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 30-DEC-2022, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On an unknown date, an unknown time after receiving Shingrix, the patient experienced feeling unwell (Verbatim: Malaise/feeling sick), low grade fever (Verbatim: Low grade fever), pain in arm (Verbatim: Sore arm) and swelling (Verbatim: Swelling). The outcome of the feeling unwell was resolved (duration 1 week) and the outcome of the low grade fever, pain in arm and swelling were resolved (duration 2 weeks).   It was unknown if the reporter considered the feeling unwell, low grade fever, pain in arm and swelling to be related to Shingrix.     It was unknown if the company considered the feeling unwell, low grade fever, pain in arm and swelling to be related to Shingrix.   Additional Information: GSK receipt date: 17-May-2023 The physician reported that the patient received dose of Shingrix in clinic.  The patient experienced feeling sick for 1 week afterwards, malaise, low grade fever, sore arm and swelling for 2 weeks.  The patient refused 2nd dose.
Age: 62.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site urticaria, Wrong technique in product usage process
Clinical narrative: whelp at the injection site; hives; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site wheal in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 05-MAY-2023, the patient received the 2nd dose of Shingrix. On 14-MAY-2023, 9 days after receiving Shingrix, the patient experienced injection site wheal (Verbatim: whelp at the injection site) and hives (Verbatim: hives). The outcome of the injection site wheal and hives were not resolved.   It was unknown if the reporter considered the injection site wheal and hives to be related to Shingrix.     It was unknown if the company considered the injection site wheal and hives to be related to Shingrix.   Additional Information: GSK Receipt Date: 16-MAY-2023 Consumer called and reported that she received dose 9 days after developed a whelp at the injections site and hives. Adverse event was filled. The reporter did not consent to follow up.
Sex: F
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: Late 2nd dose/ went to receive the 2nd dose of Shingrix, but it had passed at least one year after 1st dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received at least one year ago).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: Late 2nd dose/ went to receive the 2nd dose of Shingrix, but it had passed at least one year after 1st dose). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 18-MAY-2023 The reporter called and reported that the patient went to receive 2nd dose of Shingrix, but it had passed at least one year after the 1st dose of the Shingrix. The reporter did not consent to follow up. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.
Age: 81.0
Sex: F
Vaccine: VARZOS
Symptoms: Inappropriate schedule of product administration
Clinical narrative: patient received first dose for Shingrix in 2021 and then a second dose in 2023; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 81-year-old female patient who received Herpes zoster (Shingrix) (batch number 7KB9, expiry date 17-FEB-2024) for prophylaxis.   Previously administered products included Shingrix (patient received first dose of Shingrix on 16th July 2021, batch number MB7RR and expiry date 8th October 2022).   On 14-FEB-2023, the patient received the 2nd dose of Shingrix. On 14-FEB-2023, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: patient received first dose for Shingrix in 2021 and then a second dose in 2023). The outcome of the drug dose administration interval too long was unknown.   Additional Information: GSK Receipt Date: 18-MAY-2023 Pharmacist called to report that the patient received 2nd dose in 2023. The vaccine administration facility was same as the primary reporter. The patient received the 2nd dose of Shingrix later than recommended interval, which led to lengthening of vaccination schedule. The reporter consented to follow up via email.
Sex: U
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: received a first dose of Shingrix a year ago and then the patient did not received the second dose after 2-6 months; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received a first dose of Shingrix a year ago).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: received a first dose of Shingrix a year ago and then the patient did not received the second dose after 2-6 months). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 18-MAY-2023 The pharmacist called to ask for information about the patient who did not receive the 2nd dose after 2 to 6 months. The health care professional asked if the patient had to restart the vaccine series. The reporter did not provide the patient information nor data about the first Shingrix dose. Till the time of reporting the patient did not receive the second dose, which led to incomplete course of vaccination. The follow up request was not requested during the call.
Age: 11.0
Sex: M
Vaccine: HPV9, MNQ, TDAP
Symptoms: Erythema, Peripheral swelling, Pyrexia, Tenderness
Clinical narrative: Upper extremity swelling, erythema, and tenderness gradually worsening/spreading over 2 days. Fever to 101F. Treated with Tylenol and Motrin. Also initially given IV Clindamycin x 1 for concern for cellulitis.
Age: 78.0
Sex: F
Vaccine: COVID19-2
Symptoms: Hypoaesthesia, Raynaud's phenomenon, Skin discolouration
Clinical narrative: Fingers numb, turned  and became numb. Occurred on both hands at different times. Raynauds.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Injection site hypoaesthesia, Injection site pain, Injection site paraesthesia, Paraesthesia
Clinical narrative: Site: Pain at Injection Site-Medium, Systemic: Joint Pain-Medium, Systemic: Numbness (specify: facial area, extremities)-Medium, Error: Shoulder Joint Injury (prolonged pain, tingling, etc.)-, Additional Details: Patient experiencing pain upon injection in shoulder.  Now has dull ache and numbess in the left shoulder.  Patient also reports tingling down his arm through his shoulder, elbow and ring/pinky finger.
Age: 17.0
Sex: F
Vaccine: HEP
Symptoms: Unevaluable event
Clinical narrative: NO COMPLAINTS OR CONCERNS.
Age: 17.0
Sex: F
Vaccine: HEP
Symptoms: Unevaluable event
Clinical narrative: NO COMPLAINTS OR CONCERNS
Age: 73.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site bruising
Clinical narrative: Site: Bruising at Injection Site-Medium
Age: 72.0
Sex: F
Vaccine: COVID19-2
Symptoms: Injection site pain
Clinical narrative: Site: Pain at Injection Site-Medium
Age: 17.0
Sex: M
Vaccine: HEP
Symptoms: Unevaluable event
Clinical narrative: NO COMPLAINTS OR CONCERNS.
Age: 13.0
Sex: F
Vaccine: HEP
Symptoms: Unevaluable event
Clinical narrative: NO COMPLAINTS OR CONCERNS
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Acute psychosis, Anxiety, Confusional state, Delusion of grandeur, Delusion of parasitosis
Clinical narrative: Individual observed through social media suffering the following conditions. Causality could not be confirmed, but all events followed Covid vaccination. Events were not confirmed with psychiatric or medical personnel as the individual is not willing to seek treatment: Acute Psychosis: Extremely confused thinking, insists that VAERS is causal data no matter how often the VAERS disclaimer is shown. Delusion of Grandeur: Considers himself a biostatistician and professional in polling, despite no training and clear lack of expertise. Delusion of Parasitosis: Thinks the Covid-19 vaccine will have events first appearing even years after the fact, despite all evidence to the contrary. Considers the spike protein from the vaccine significantly more dangerous than that from the virus. Somatic delusions: Constantly worries about unproven adverse events from the Covid vaccine, despite no scientific evidence of the vaccines causing them. As he is vaccinated, he likely has serious concerns about his own health. Persecutory delusions: Concerned that his free speech is being taken away because he is not allowed to spread his delusions unchecked through online forums owned by private individuals, believing that his rights to free speech trump theirs. Mixed Delusion: Self explanatory.  All evidence can be accessed through the individual's account and pages, with frequent displays of all of the above conditions. (Some Tests Even Verify Every Kind In Rejecting Seeking Help)
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Mental impairment, Mixed delusion, Somatic delusion
Clinical narrative: Individual observed through social media suffering the following conditions. Causality could not be confirmed, but all events followed Covid vaccination. Events were not confirmed with psychiatric or medical personnel as the individual is not willing to seek treatment: Acute Psychosis: Extremely confused thinking, insists that VAERS is causal data no matter how often the VAERS disclaimer is shown. Delusion of Grandeur: Considers himself a biostatistician and professional in polling, despite no training and clear lack of expertise. Delusion of Parasitosis: Thinks the Covid-19 vaccine will have events first appearing even years after the fact, despite all evidence to the contrary. Considers the spike protein from the vaccine significantly more dangerous than that from the virus. Somatic delusions: Constantly worries about unproven adverse events from the Covid vaccine, despite no scientific evidence of the vaccines causing them. As he is vaccinated, he likely has serious concerns about his own health. Persecutory delusions: Concerned that his free speech is being taken away because he is not allowed to spread his delusions unchecked through online forums owned by private individuals, believing that his rights to free speech trump theirs. Mixed Delusion: Self explanatory.  All evidence can be accessed through the individual's account and pages, with frequent displays of all of the above conditions. (Some Tests Even Verify Every Kind In Rejecting Seeking Help)
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoxia, Symptom recurrence
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE HYPOXIA 10/13/2022,  10/29/2022,  12/8/2022 -- RECURRENCE OF SAME SYMPTOMS
Age: 6.0
Sex: M
Vaccine: COVID19-2
Symptoms: Injection site pain, Product administration error, Product preparation error
Clinical narrative: error made: no diluent used Received concentrated dose, approx 28mg given instead of 10 mcg outcome - no fever. & soreness at injection site within 24 H. Otherwise   no           symptoms.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Hypersensitivity
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE ALLERGIC DISORDER, INIT
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoxia
Clinical narrative: HYPOXIA
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Symptom recurrence
Clinical narrative: ACUTE RESPIRATORY FAILURE 6/10/2022 -- RECURRENCE OF SAME SYMPTOMS
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoxia
Clinical narrative: HYPOXIA
Age: 86.0
Sex: M
Vaccine: COVID19
Symptoms: Deep vein thrombosis
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE ACUTE DVT, UNSPECIFIED VEIN ACUTE DVT OF BILAT FEMORAL VEINS
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Ischaemic stroke
Clinical narrative: ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Angioedema
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE ANGIOEDEMA, INIT
Age: 71.0
Sex: F
Vaccine: COVID19-2
Symptoms: Injection site erythema, Injection site warmth
Clinical narrative: Pt's arm was red and warm to touch at a site a few inches from  injecting site. Pt will let dr know if it becomes painful or increases in size.
Age: 79.0
Sex: M
Vaccine: COVID19-2
Symptoms: Acute respiratory failure
Clinical narrative: ACUTE HYPOXEMIC RESPIRATORY FAILURE
Age: 66.0
Sex: F
Vaccine: VARZOS
Symptoms: Arthralgia, Chills, Limb discomfort, Lymphadenopathy, Neuralgia
Clinical narrative: First I started having severe pain over the entire shoulder, lasting 72 hours at this time. Next event, was fever of 102 and chills, then the next event was the enlargement of the lymph nodes in the arm pit- left. With irritation of the nerve, with tingling and irritation of the hand. Pain, enlargement of lymph nodes, fever and chills. The pain was out of portion of what I have ever received. The enlarged lymph node was very painful and irritated the nerve. I did not seek any medical care for it.
Age: 66.0
Sex: F
Vaccine: VARZOS
Symptoms: Pain, Paraesthesia, Pyrexia
Clinical narrative: First I started having severe pain over the entire shoulder, lasting 72 hours at this time. Next event, was fever of 102 and chills, then the next event was the enlargement of the lymph nodes in the arm pit- left. With irritation of the nerve, with tingling and irritation of the hand. Pain, enlargement of lymph nodes, fever and chills. The pain was out of portion of what I have ever received. The enlarged lymph node was very painful and irritated the nerve. I did not seek any medical care for it.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: ADULT OBSTRUCTIVE SLEEP APNEA, SEVERE
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Hypotension
Clinical narrative: CHRONIC HYPOTENSION
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Nasal congestion, Nasopharyngitis, SARS-CoV-2 test positive
Clinical narrative: I woke up in the morning with a cold and minor nasal congestion, I had flown two days before to my home, went to an urgent care facility and tested positive for COVID-19.
Age: 54.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site reaction, Injection site swelling, Injection site warmth
Clinical narrative: injection site reaction    swollen, red, feverish at site for 3 days following injection
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Lacunar stroke
Clinical narrative: ACUTE LACUNAR STROKE, UNSPECIFIED TYPE AND ARTERY
Age: 0.33
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC13, RV5
Symptoms: Faeces discoloured, Infant irritability, Mucous stools, Occult blood positive, Ultrasound abdomen normal
Clinical narrative: Last 5/16/23 around 1:30PM mom called our office and informed us that patient had reddish mucus in the stool after their appointment with us. 2 hours later, mom informed us and described it as "strawberry jelly mucus". No fever, no vomiting, abdomen was soft, patient a little bit fussy. Talked the situation to the provider.  He spoke to parents about the concerns and plan. The provider ordered stat ultrasound abdomen and stat occult blood screen. But the patient ended up being seen in the ER d/t almost past office hours of the clinic and occult blood sample was not accepted at the lab because it has to be in a stool container and that sample may be contaminated with urine. Patient was transferred to facility
Age: 0.33
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC13, RV5
Symptoms: Urinary system X-ray, Urinary tract imaging normal
Clinical narrative: Last 5/16/23 around 1:30PM mom called our office and informed us that patient had reddish mucus in the stool after their appointment with us. 2 hours later, mom informed us and described it as "strawberry jelly mucus". No fever, no vomiting, abdomen was soft, patient a little bit fussy. Talked the situation to the provider.  He spoke to parents about the concerns and plan. The provider ordered stat ultrasound abdomen and stat occult blood screen. But the patient ended up being seen in the ER d/t almost past office hours of the clinic and occult blood sample was not accepted at the lab because it has to be in a stool container and that sample may be contaminated with urine. Patient was transferred to facility
Age: 87.0
Sex: F
Vaccine: COVID19
Symptoms: Neuropathy peripheral, Symptom recurrence
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE NEUROPATHY 8/25/2022,  10/31/2022,  11/2/2022 -- RECURRENCE OF SAME SYMPTOMS
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Ischaemic stroke
Clinical narrative: ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY
Age: 100.0
Sex: M
Vaccine: COVID19-2
Symptoms: Acute pulmonary oedema, Chronic obstructive pulmonary disease, Condition aggravated, Fall, Joint injury
Clinical narrative: Patient was brought to the local ER via ambulance from another facility with c/o a fall with injury to left hip, also wheezing.  Patient was evaluated and admitted for acute exacerbation of COPD with acute pulmonary edema.
Age: 100.0
Sex: M
Vaccine: COVID19-2
Symptoms: Wheezing
Clinical narrative: Patient was brought to the local ER via ambulance from another facility with c/o a fall with injury to left hip, also wheezing.  Patient was evaluated and admitted for acute exacerbation of COPD with acute pulmonary edema.
Age: 3.0
Sex: F
Vaccine: DTAP, IPV
Symptoms: Expired product administered
Clinical narrative: The DTaP we gave this pt was expired on 5/11/23, and we gave the vaccine on 5/15/23 by accident.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: OBSTRUCTIVE SLEEP APNEA
Age: 1.33
Sex: M
Vaccine: DTAPHEPBIP, HIBV, PNC13
Symptoms: Wrong product administered
Clinical narrative: Was given pediarix instead of the infanrix he was due for.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE ACUTE NON ST ELEVATION MI ACUTE MI
Age: 72.0
Sex: F
Vaccine: COVID19-2
Symptoms: Abdominal X-ray, Blood test abnormal, Cholelithiasis, Computerised tomogram abdomen abnormal, Fall
Clinical narrative: I had a hard time early in the morning getting out of bed. I had to have my husband help me. I went to the bathroom on the way back I fell, He could not get me up off the floor and I could not help enough to get myself up. He called help assist to get me up, they took me to the hospital, to find out what was going on with me. Once I arrived at the hospital, they started running test. I had bloodwork that came showing I had an infection, x-ray and CT scan that showed I had gallstones. An ultrasound was ordered to find out how big they were, the ultrasound revealed some of the stones are .7mm in size. I stayed in the hospital for three days until they felt the infection was cleared up enough for me to leave. I will be having the gallstones removed as soon as I am able to get back into the hospital.
Age: 72.0
Sex: F
Vaccine: COVID19-2
Symptoms: Infection, Mobility decreased, Ultrasound abdomen abnormal, Urine analysis abnormal
Clinical narrative: I had a hard time early in the morning getting out of bed. I had to have my husband help me. I went to the bathroom on the way back I fell, He could not get me up off the floor and I could not help enough to get myself up. He called help assist to get me up, they took me to the hospital, to find out what was going on with me. Once I arrived at the hospital, they started running test. I had bloodwork that came showing I had an infection, x-ray and CT scan that showed I had gallstones. An ultrasound was ordered to find out how big they were, the ultrasound revealed some of the stones are .7mm in size. I stayed in the hospital for three days until they felt the infection was cleared up enough for me to leave. I will be having the gallstones removed as soon as I am able to get back into the hospital.
Age: 90.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive
Clinical narrative: 3rd DOSE MODERNA COVID VACCINE GIVEN 8/31/22, #055A22A; 8/15/2022 Pt had a positive COVID test in Health Center; DNR; comfort care only; pt passed away in the SNF.  FNP, NP took care of this pt at Health Center.
Age: 19.0
Sex: M
Vaccine: HEP
Symptoms: Extra dose administered
Clinical narrative: patient was 19 years old at the time of  given vaccine form state.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Narcolepsy, Symptom recurrence
Clinical narrative: NARCOLEPSY, UNSPECIFIED 3/27/2022,  5/13/2022,  5/17/2022,  5/29/2022,  7/26/2022,  8/3/2022,  8/26/2022,  10/29/2022,   1/2/2023,  12/25/2022  -- RECURRENCE OF SAME SYMPTOMS
Age: 79.0
Sex: M
Vaccine: COVID19-2, COVID19-2
Symptoms: Chills, Fatigue, Feeling cold, Insomnia, Pain
Clinical narrative: Symptoms started about 10:00 PM on Saturday, 5-20-23.  I felt cold and began shivering badly.  I crawled under the blanket and, several minutes later, the shivering stopped.  I woke up every 15-20 minutes throughout the night because of mild aches.  Whenever I had to go to the bathroom the cold and shivering started again.  The symptoms slowly decreased in the early morning.  because of lack of sleep, I was tired for the next two days.
Age: 79.0
Sex: M
Vaccine: COVID19-2, COVID19-2
Symptoms: Sleep disorder
Clinical narrative: Symptoms started about 10:00 PM on Saturday, 5-20-23.  I felt cold and began shivering badly.  I crawled under the blanket and, several minutes later, the shivering stopped.  I woke up every 15-20 minutes throughout the night because of mild aches.  Whenever I had to go to the bathroom the cold and shivering started again.  The symptoms slowly decreased in the early morning.  because of lack of sleep, I was tired for the next two days.
Age: 1.58
Sex: M
Vaccine: DTAP, IPV
Symptoms: Expired product administered, No adverse event
Clinical narrative: We gave an expired DTaP. Expiration date was 5/11/23, and we gave the vaccine on 5/15/23, accidentally. No adverse reaction.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Haemorrhagic disorder, Pulmonary embolism
Clinical narrative: I26.99 ACUTE PULMONARY EMBOLISM 7/20/2022 HEMORRHAGIC D/O DUE EXTRINSIC CIRC ANTICOAGULANT
Age: 0.5
Sex: M
Vaccine: COVID19-2
Symptoms: Wrong product administered
Clinical narrative: Pt was given the incorrect COVID vaccine
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoxia, Pulmonary embolism, Symptom recurrence
Clinical narrative: ACUTE PULMONARY EMBOLISM HYPOXIA 2/18/2022 -- RECURRENCE OF SAME SYMPTOMS
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Atrial tachycardia, Deep vein thrombosis, Pulmonary embolism
Clinical narrative: PULMONARY EMBOLISM, UNSPECIFIED. 2/1/2022 ATRIAL TACHYCARDIA  ACUTE DVT OF RIGHT POPLITEAL VEIN 2/1/2022 ATRIAL TACHYCARDIA  PULMONARY EMBOLISM, UNSPECIFIED. 2/1/2022 ATRIAL TACHYCARDIA  ACUTE DVT OF RIGHT POPLITEAL VEIN 2/1/2022 ATRIAL TACHYCARDIA
Age: 40.0
Sex: F
Vaccine: HEP, MMR, TD, VARCEL
Symptoms: Expired product administered
Clinical narrative: Administered an expired dose of TD vaccine to patient. Vial was expired by one day.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction
Clinical narrative: ACUTE ST ELEVATION MI, ANTERIOR WALL
Age: 66.0
Sex: F
Vaccine: COVID19-2, FLU4
Symptoms: Burning sensation, Pollakiuria, Urinary tract infection, Urine analysis abnormal
Clinical narrative: I started having frequent trips to the bathroom to urinate, some burning sensation. I called to make an appointment with my doctor. I had a urinalysis test during my visit with the doctor visit where it was determined I had an UTI infection. I was prescribed medication for the UTI that I was able to start immediately.
Age: 57.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, Cough, Fatigue, Headache, Pain
Clinical narrative: I tested positive for COVID-19 on April 09, 2023 my symptoms were aches, coughs, & fatigue and had a headache for a few days. I was taking Tylenol and Ibuprofen.
Age: 57.0
Sex: F
Vaccine: COVID19-2
Symptoms: SARS-CoV-2 test positive
Clinical narrative: I tested positive for COVID-19 on April 09, 2023 my symptoms were aches, coughs, & fatigue and had a headache for a few days. I was taking Tylenol and Ibuprofen.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoxia, Ischaemic stroke, Obstructive sleep apnoea syndrome
Clinical narrative: OBSTRUCTIVE SLEEP APNEA ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY HYPOXIA
Age: 78.0
Sex: F
Vaccine: COVID19-2
Symptoms: Anaemia, Asthenia, Blood test abnormal, Fatigue, Mobility decreased
Clinical narrative: On 09/16/2022 or within that week, I began to feel exhausted and had a fever and was achy.  I kept picking up viruses and my sinuses would get infected.  I would be in bed for three or four days and I still don't have the energy.
Age: 78.0
Sex: F
Vaccine: COVID19-2
Symptoms: Pain, Pyrexia, Sinusitis, Viral infection
Clinical narrative: On 09/16/2022 or within that week, I began to feel exhausted and had a fever and was achy.  I kept picking up viruses and my sinuses would get infected.  I would be in bed for three or four days and I still don't have the energy.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Embolic stroke, Essential hypertension, Transient ischaemic attack
Clinical narrative: G45.9 TRANSIENT CEREBRAL ISCHEMIA 5/14/2022 ACUTE STROKE DUE TO EMBOLISM OF UNSPECIFIED ARTERY I63.9 ACUTE STROKE DUE TO EMBOLISM OF UNSPECIFIED ARTERY 5/14/2022 ACUTE STROKE DUE TO EMBOLISM OF UNSPECIFIED ARTERY J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 12/23/2022 ACUTE STROKE DUE TO EMBOLISM OF UNSPECIFIED ARTERY G45.9 TRANSIENT CEREBRAL ISCHEMIA 5/14/2022 ESSENTIAL HTN I63.9 ACUTE STROKE DUE TO EMBOLISM OF UNSPECIFIED ARTERY 5/14/2022 ESSENTIAL HTN J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 12/23/2022 ESSENTIAL HTN
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Anticoagulant therapy, COVID-19, Cardiac arrest, Death, Gastrointestinal haemorrhage
Clinical narrative: pt to hospital with GI bleed (on Coumadin) on 8/14/22; received 2 U of PRBC transfusion; DNR;  pt had a positive COVID test on 8/22/2022 at a local healthcare center; was asymptomatic and required no therapies for COVID; suffered V-Tach cardiac arrest and passed away in the hospital
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Red blood cell transfusion, SARS-CoV-2 test positive, Ventricular tachycardia
Clinical narrative: pt to hospital with GI bleed (on Coumadin) on 8/14/22; received 2 U of PRBC transfusion; DNR;  pt had a positive COVID test on 8/22/2022 at a local healthcare center; was asymptomatic and required no therapies for COVID; suffered V-Tach cardiac arrest and passed away in the hospital
Age: 0.42
Sex: F
Vaccine: COVID19
Symptoms: Discontinued product administered
Clinical narrative: Pt received incorrect COVID vaccine
Age: 65.0
Sex: M
Vaccine: PPV
Symptoms: Erythema, Induration
Clinical narrative: erythema, induration wrapping around arm
Age: 15.0
Sex: M
Vaccine: HEPA, HPV9, IPV, MMRV, MNQ, TDAP
Symptoms: No adverse event, Product administered to patient of inappropriate age, Vaccination error
Clinical narrative: 5/22/2023 0955 Patient is 15 years old and was administered ProQuad(MMRV) SQ right arm on 5/17/2023. The patient should have been administered MMR and Varicella separately. ProQuad is not to be administered to patients 13 years or older. Patient tolerated the vaccines well and did not have any adverse reactions.
Age: 93.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Acute left ventricular failure, Acute respiratory failure, COVID-19, Condition aggravated, Cough
Clinical narrative: BREAKTHROUGH COVID: FULLY VACINATTED 94-year-old female who presents to the ED on 6/1/2022 after a fall at home as well as with difficulty breathing, cough, lethargy and decreased appetitie for past few days. On arrival her O2 sats were 80%on RA.   Initially she was started on BiPAP and admitted to the ICU under critical care.  She has hx of OSA and Acute respiratory failure present on arrival.Diagnosised with acute distal HF with exacerbation, pernicious anemia.  She was noted to have pulmonary edema and was given iv  diuretics and her breathing improved. She is currently on 4 L nasal cannula. She was + for COVID PCR.  Patient was treated with Decadron. Treated and weaned off oxygen completely.
Age: 93.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Decreased appetite, Dyspnoea, Fall, Intensive care, Lethargy
Clinical narrative: BREAKTHROUGH COVID: FULLY VACINATTED 94-year-old female who presents to the ED on 6/1/2022 after a fall at home as well as with difficulty breathing, cough, lethargy and decreased appetitie for past few days. On arrival her O2 sats were 80%on RA.   Initially she was started on BiPAP and admitted to the ICU under critical care.  She has hx of OSA and Acute respiratory failure present on arrival.Diagnosised with acute distal HF with exacerbation, pernicious anemia.  She was noted to have pulmonary edema and was given iv  diuretics and her breathing improved. She is currently on 4 L nasal cannula. She was + for COVID PCR.  Patient was treated with Decadron. Treated and weaned off oxygen completely.
Age: 93.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pernicious anaemia, Positive airway pressure therapy, Pulmonary oedema, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: BREAKTHROUGH COVID: FULLY VACINATTED 94-year-old female who presents to the ED on 6/1/2022 after a fall at home as well as with difficulty breathing, cough, lethargy and decreased appetitie for past few days. On arrival her O2 sats were 80%on RA.   Initially she was started on BiPAP and admitted to the ICU under critical care.  She has hx of OSA and Acute respiratory failure present on arrival.Diagnosised with acute distal HF with exacerbation, pernicious anemia.  She was noted to have pulmonary edema and was given iv  diuretics and her breathing improved. She is currently on 4 L nasal cannula. She was + for COVID PCR.  Patient was treated with Decadron. Treated and weaned off oxygen completely.
Age: 66.0
Sex: M
Vaccine: PNC20
Symptoms: Erythema, Induration
Clinical narrative: erythema, induration wrapping around arm